Home

Cormorant Private Healthcare Fund III LP

CIK 1817320 · last filed 2025-06-13

Cormorant Private Healthcare Fund III LP is a corporate insider who has filed 6 SEC Form 4 insider transactions across 5 companies since 2021. The most recent filing, for BMEA, was dated Jun 13, 2025. Across all open-market trades the lifetime net is +$410.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $72.1M across reported positions. The firm reports its address in Boston, MA. 51 SEC filings were submitted jointly with Bihua Chen.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$72.12M

Companies

5

Total Filings

6

Lifetime Open-Market Net

$410.80M

Filer Profile

Reported Address
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA 02116
Phone
(857) 702-0370
State of Incorporation
DE
Related Filers
Bihua Chen — 51 joint filings, latest 2026-08-10
Cormorant Asset Management, LP — 51 joint filings, latest 2026-08-10
Cormorant Global Healthcare Master Fund, LP — 51 joint filings, latest 2026-08-10
Cormorant Private Healthcare Fund II, LP — 11 joint filings, latest 2025-10-01
Cormorant Private Healthcare Fund IV LP — 6 joint filings, latest 2025-10-01
Cormorant Private Healthcare Fund V LP — 5 joint filings, latest 2026-08-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BMEA 10%+ Owner 3,570,872 $1.74 $6.21M $0 1 2025-06-13
Ambrx Biopharma Inc. (AMAM) Delisted 10%+ Owner 65,474,542 $28.00 $1.83B $276.65M 2 2023-04-20
Verve Therapeutics, Inc. (VERV) Delisted 984,224 $11.13 $10.95M $20.90M 1 2021-06-23
RAIN 2,776,657 $0.74 $2.05M $38.25M 1 2021-04-29
DSGN 4,364,844 $14.63 $63.86M $75.00M 1 2021-04-01

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-06-13 BMEA Grant (A) — $0 EDGAR
2023-04-20 Ambrx Biopharma Inc. (AMAM) Delisted Buy (P) +20,860,756 $235.80M EDGAR
2023-03-16 Ambrx Biopharma Inc. (AMAM) Delisted Buy (P) +4,000,000 $40.85M EDGAR
2021-06-23 Verve Therapeutics, Inc. (VERV) Delisted Mixed +3,936,896 $20.90M EDGAR
2021-04-29 RAIN Mixed +13,883,285 $38.25M EDGAR
2021-04-01 DSGN Mixed +25,574,220 $75.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.